Inhibition of miR-34b and miR-34c enhances α-synuclein expression in Parkinson's disease

FEBS Letters

Volumn 589, Issue 3, 2015, Pages 319-325

  Kabaria, Savan ^a   Choi, Doo Chul ^a   Chaudhuri, Amrita Datta ^a   Mouradian, M Maral ^a   Junn, Eunsung ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

microRNA 34b; microRNA 34c; Parkinson' disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; MICRORNA; MICRORNA 34B; MICRORNA 34C; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN34 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; PARKINSON DISEASE; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN; CELL LINE; GENETICS; METABOLISM; PATHOLOGY;

3' UNTRANSLATED REGIONS; ALPHA-SYNUCLEIN; BRAIN; CELL LINE; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84921521998     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.12.014     Document Type: Article

References (26)

1. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. and Goedert, M. (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95, 6469-6473.
2. Narhi, L., Wood, S.J., Steavenson, S., Jiang, Y., Wu, G.M., Anafi, D., Kaufman, S.A., Martin, F., Sitney, K., Denis, P., Louis, J.C., Wypych, J., Biere, A.L. and Citron, M. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 9843-9846.
3. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J. and Gwinn-Hardy, K. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302, 841.
4. Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D.S., Hulihan, M., Maraganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D. and Langston, J.W. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174-179.
5. Maraganore, D.M., de Andrade, M., Elbaz, A., Farrer, M.J., Ioannidis, J.P., Kruger, R., Rocca, W.A., Schneider, N.K., Lesnick, T.G., Lincoln, S.J., Hulihan, M.M., Aasly, J.O., Ashizawa, T., Chartier-Harlin, M.C., Checkoway, H., Ferrarese, C., Hadjigeorgiou, G., Hattori, N., Kawakami, H., Lambert, J.C., Lynch, T., Mellick, G.D., Papapetropoulos, S., Parsian, A., Quattrone, A., Riess, O., Tan, E.K., Van Broeckhoven, C. and Genetic Epidemiology of Parkinson's Disease Consortium (2006) Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296, 661-670.
6. Schlaudraff, F., Grundemann, J., Fauler, M., Dragicevic, E., Hardy, J. and Liss, B. (2014) Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. Neurobiol. Aging 35, 2302-2315.
7. Grundemann, J., Schlaudraff, F., Haeckel, O. and Liss, B. (2008) Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res. 36, e38.
8. Yelamanchili, S.V. and Fox, H.S. (2010) Defining larger roles for "tiny" RNA molecules: role of miRNAs in neurodegeneration research. J. Neuroimmune Pharmacol. 5, 63-69.
9. Junn, E. and Mouradian, M.M. (2012) MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol. Ther. 133, 142-150.
10. Harraz, M.M., Dawson, T.M. and Dawson, V.L. (2011) MicroRNAs in Parkinson's disease. J. Chem. Neuroanat. 42, 127-130.
11. Qiu, L., Zhang, W., Tan, E.K. and Zeng, L. (2014) Deciphering the function and regulation of microRNAs in Alzheimer's disease and Parkinson's disease. ACS Chem. Neurosci. 5, 884-894
12. Junn, E., Lee, K.W., Jeong, B.S., Chan, T.W., Im, J.Y. and Mouradian, M.M. (2009) Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U.S.A. 106, 13052-13057.
13. Doxakis, E. (2010) Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 285, 12726-12734.
14. Minones-Moyano, E., Porta, S., Escaramis, G., Rabionet, R., Iraola, S., Kagerbauer, B., Espinosa-Parrilla, Y., Ferrer, I., Estivill, X. and Marti, E. (2011) MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 20, 3067-3078.
15. Villar-Menendez, I., Porta, S., Buira, S.P., Pereira-Veiga, T., Diaz-Sanchez, S., Albasanz, J.L., Ferrer, I., Martin, M. and Barrachina, M. (2014) Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b. Neurobiol. Dis. 69, 206-214.
16. Rehmsmeier, M., Steffen, P., Hochsmann, M. and Giegerich, R. (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10, 1507-1517.
17. Cardo, L.F., Coto, E., de Mena, L., Ribacoba, R., Moris, G., Menendez, M. and Alvarez, V. (2013) Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J. Neurol. 260, 1420-1422.
18. Martins, M., Rosa, A., Guedes, L.C., Fonseca, B.V., Gotovac, K., Violante, S., Mestre, T., Coelho, M., Rosa, M.M., Martin, E.R., Vance, J.M., Outeiro, T.F., Wang, L., Borovecki, F., Ferreira, J.J. and Oliveira, S.A. (2011) Convergence of miRNA expression profiling, alpha-synuclein interaction and GWAS in Parkinson's disease. PLoS One 6, e25443.
19. Asikainen, S., Rudgalvyte, M., Heikkinen, L., Louhiranta, K., Lakso, M., Wong, G. and Nass, R. (2010) Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models. J. Mol. Neurosci. 41, 210-218.
20. Kim, J., Inoue, K., Ishii, J., Vanti, W.B., Voronov, S.V., Murchison, E., Hannon, G. and Abeliovich, A. (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317, 1220-1224.
21. Mata, I.F., Shi, M., Agarwal, P., Chung, K.A., Edwards, K.L., Factor, S.A., Galasko, D.R., Ginghina, C., Griffith, A., Higgins, D.S., Kay, D.M., Kim, H., Leverenz, J.B., Quinn, J.F., Roberts, J.W., Samii, A., Snapinn, K.W., Tsuang, D.W., Yearout, D., Zhang, J., Payami, H. and Zabetian, C.P. (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch. Neurol. 67, 1350-1356.
22. Yu, L., Xu, P., He, X., Hu, F., Lin, Z., Zhu, M., Liu, Z., He, L. and Xu, Y. (2010) SNP rs7684318 of the alpha-synuclein gene is associated with Parkinson's disease in the Han Chinese population. Brain Res. 1346, 262-265.
23. Pan, F., Dong, H., Ding, H., Ye, M., Liu, W., Wu, Y., Zhang, X., Chen, Z., Luo, Y. and Ding, X. (2012) SNP rs356219 of the alpha-synuclein (SNCA) gene is associated with Parkinson's disease in a Chinese Han population. Parkinsonism Relat. Disord. 18, 632-634.
24. Wang, G., van der Walt, J.M., Mayhew, G., Li, Y.J., Zuchner, S., Scott, W.K., Martin, E.R. and Vance, J.M. (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet. 82, 283-289.
25. de Mena, L., Cardo, L.F., Coto, E., Miar, A., Diaz, M., Corao, A.I., Alonso, B., Ribacoba, R., Salvador, C., Menendez, M., Moris, G. and Alvarez, V. (2010) FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients. Neurosci. Lett. 479, 22-25.
26. Wider, C., Dachsel, J.C., Soto, A.I., Heckman, M.G., Diehl, N.N., Yue, M., Lincoln, S., Aasly, J.O., Haugarvoll, K., Trojanowski, J.Q., Papapetropoulos, S., Mash, D., Rajput, A., Rajput, A.H., Gibson, J.M., Lynch, T., Dickson, D.W., Uitti, R.J., Wszolek, Z.K., Farrer, M.J. and Ross, O.A. (2009) FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov. Disord. 24, 455-459.